Hisamitsu's transdermal oxybutynin set for Phase III
07 August 2009
Ian Haydock
Please Login to read the full article.
07 August 2009
Ian Haydock
ian.haydock@informa.com
Hisamitsu is planning to take a transdermal formulation of the muscarinic antagonist oxybutynin hydrochloride (HOB-294) into Phase III development for overactive bladder symptoms following positive results in a Japanese trial.
The eight-week Phase II study compared the once-daily patch preparation...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US and EU filings for Astellas' first-in-class OAB drug mirabegron
- Preliminary Japanese nod moves mirabegron closer to first market
- Kyorin pact another arrow in Daiichi Sankyo's South American quiver
- European positive opinion for Allergan's Botox for neurogenic bladder incontinence
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
